RaQualia Pharma Inc.
4579
Rank in Stocks
#19182
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a... RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Share Price
$4.29
Last synced: 2026-11-10
Market Cap
$111.71M
Change (1 day)
4.31%
Change (1 year)
28.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade RaQualia Pharma Inc. (4579)
Category
Healthcare
Operating Margin for RaQualia Pharma Inc. (4579)
Operating Margin as of November 2026 TTM: 8.60%
According to RaQualia Pharma Inc.'s latest financial reports, its current operating margin (TTM) is 8.60%. At the end of 2025 the company had an operating margin of 12.15%.
Operating Margin history for RaQualia Pharma Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 8.60% | -29.22% |
| 2025 | 12.15% | -276.86% |
| 2024 | -6.87% | -61.27% |
| 2023 | -17.74% | -159.75% |
| 2022 | 29.69% | 16.43% |
| 2021 | 25.50% | -158.09% |
| 2020 | -43.90% | 2,788.16% |
| 2019 | -1.52% | -98.95% |
| 2018 | -144.40% | 1,262.26% |
| 2017 | -10.60% | -90.16% |
| 2016 | -107.75% | -91.59% |
| 2015 | -1,281.51% | -9.68% |
| 2014 | -1,418.87% | 51.34% |
| 2013 | -937.53% | -89.70% |
| 2012 | -9,099.65% | 3,148.48% |
| 2011 | -280.12% | 147.06% |
| 2010 | -113.38% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -121.09% |
US
|
|
| 38.59% | -95.51% |
US
|
|
| -149.01% | -117.33% |
US
|
|
| 25.57% | -97.03% |
AU
|
|
| 31.23% | -96.37% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about RaQualia Pharma Inc.'s operating margin
What is RaQualia Pharma Inc.'s operating margin?
RaQualia Pharma Inc.'s operating margin is 8.60%, as of Nov 2026.
What was RaQualia Pharma Inc.'s operating margin in 2025?
In 2025, RaQualia Pharma Inc.'s operating margin was 12.15%, compared with -6.87% in 2024.
How has RaQualia Pharma Inc.'s operating margin changed since 2020?
From 2020 to 2025, RaQualia Pharma Inc.'s operating margin was highest in 2022 (29.69%) and lowest in 2020 (-43.90%).
How does RaQualia Pharma Inc.'s operating margin compare with similar companies?
RaQualia Pharma Inc.'s operating margin (8.60%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.